PARIS—Cystoscopy prior to low dose rate (LDR) brachytherapy for prostate cancer is feasible and useful in identifying patients who require further investigation or intervention before seed implantation, researchers reported at the 27th Annual Congress of the European Association of Urology.
Nicholas J. Mehan, MD, and colleagues at St. George Hospital in Sydney, Australia, reported data from a prospective study of 440 men treated with LDR brachytherapy. As part of a routine protocol, all patients underwent pretreatment cystoscopy, which revealed abnormalities in 59 (13.4%) of the 440 patients. Thirty-two patients (7.2%) had a prominent middle lobe of the prostate, nine (2%) had anterior urethral strictures, seven (1.6%) had bladder calculi, four (0.9%) had transitional cell carcinoma of the bladder, and eight (1.8%) had benign urothelial abnormalities.
Based on the cystoscopic findings, 46 patients (10.5%) had interventions, such as middle lobe resection and stricture dilation, and transurethral resection of the bladder.